NewAmsterdam Pharma Company N.V. (NAMS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

NewAmsterdam Pharma Company N.V. (NAMS) closed at USD 20.01 on 2026-10-14, a change of -44.6 % over the past year, with a market capitalization of USD 2.46B.

NewAmsterdam Pharma Company N.V. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NewAmsterdam Pharma Company N.V. key figures

Previous close

USD 20.01 (2026-10-14)

1-year change

-44.6 %

Market cap

USD 2.46B

Enterprise value

USD 1.83B

P/E ratio (trailing)

-9.33

P/E ratio (forward)

-13.51

EPS (trailing)

-2.21

EPS (forward)

-1.53

PEG ratio

n/a

Price to book

3.84

Revenue growth

-80.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.36

Employees

100

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NewAmsterdam Pharma Company N.V. and compare it with other stocks.